Drupal.behaviors.print = function(context) {window.print();window.close();}>
Vermillion Lowers Price Target on Public Offering
February 14, 2011
Vermillion Lowers Price Target on Public Offering
The company has lowered its price target to up to $29.9 million from as much as $33.9 million.
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Vermillion Posts 8 Percent Increase in OVA1 Sales, Announces Shift in Commercialization Strategy
May 17, 2013 / ProteoMonitor
Vermillion's OVA1 Sales Increase 8 Percent in Q1
May 16, 2013 / GenomeWeb Daily News
GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor
Vermillion to Raise up to $31.5M in Equity Financing
May 9, 2013 / GenomeWeb Daily News
Vermillion Inks CRADA with Army to Evaluate OVA1
April 17, 2013 / GenomeWeb Daily News